The current study was conducted to investigate survival and the response to radiotherapy among patients with molecular subtypes of breast cancer brain metastases treated with or without targeted therapies. METHODS: Patients diagnosed with breast cancer brain metastases at a single tertiary care institution were included. The primary outcome was overall survival, whereas secondary outcomes included the cumulative incidences of distant intracranial failure, local failure, and radiation necrosis. Competing risks regression was used to model secondary outcomes. RESULTS: Within the study period, 547 patients presented with 3224 brain metastases and met inclusion criteria. Among patients with human epidermal growth factor receptor 2 (HER2)-amplified disease, 80% received HER2 antibodies and 38% received HER2/epidermal growth factor receptor tyrosine kinase inhibitors (TKIs). The median survival was significantly shorter in the basal cohort (8.4 months), and progressively increased in the luminal A (12.3 months), HER2-positive (15.4 months), and luminal B (18.8 months) cohorts (P<.001). Among patients with HER2-amplified disease, the median survival was extended with the use of both HER2 antibodies (17.9 months vs 15.1 months; P 5.04) and TKIs (21.1 months vs 15.4 months; P 5.03). The 12-month cumulative incidences of local failure among molecular subtypes were 6.0% in the luminal A cohort, 10.3% in the luminal B cohort, 15.4% in the HER2-positive cohort, and 9.9% in the basal cohort (P 5.01). Concurrent HER2/epidermal growth factor receptor TKIs with stereotactic radiosurgery significantly decreased the 12-month cumulative incidence of local failure from 15.1% to 5.7% (P<.001). CONCLUSIONS: Molecular subtypes appear to be prognostic for survival and predictive of the response to radiotherapy. TKIs were found to improve survival and local control, and may decrease the rate of distant failure. To preserve neurocognition, these results support a paradigm of upfront radiosurgery and HER2-directed therapy in the HER2-amplified population, reserving whole-brain radiotherapy for salvage. Cancer 2017;123:2283-93. V C 2017 American Cancer Society.
INTRODUCTION
Breast cancer is the second leading cause of brain metastasis and cancer-related mortality among women in the United States. 1, 2 Approximately 5% of patients diagnosed with breast cancer eventually develop brain metastasis, with a median survival of 14 months. 3, 4 Hormone receptor and human epidermal growth factor receptor 2 (HER2) amplification status have clear prognostic and predictive implications, and correlate with molecular subtypes of breast cancer. 5 These subtypes have been incorporated into various prognostic models for survival, including the diagnosis-specific graded prognostic assessment (DS-GPA). 4, 6 There have been some data suggesting an increased propensity for brain metastasis among basallike breast cancers, for which targeted therapies are ineffective. [7] [8] [9] Moreover, among patients who develop HER2-amplified metastatic breast cancer, the brain is increasingly being recognized as a common site of disease recurrence, perhaps due to extended survival and the poor penetration of HER2-directed antibodies into the central nervous system (CNS). [10] [11] [12] Although the prognosis of this patient population has been studied, the relation between molecular subtypes, targeted therapies, and the response to radiotherapy (RT) remains unclear. Whole-brain RT (WBRT) remains the primary modality for distant intracranial control, whereas stereotactic radiosurgery (SRS) offers effective local control. Given the favorable prognosis of patients with HER2-amplified disease, the omission of upfront WBRT is desirable to prevent late neurocognitive toxicity. 13 Unfortunately, HER2-directed antibodies poorly penetrate the bloodbrain barrier and appear to provide an unclear benefit for patients with brain metastasis.
14 Small studies have suggested increased intracranial control with the use of dual HER2/epidermal growth factor receptor (EGFR) smallmolecule tyrosine kinase inhibitors (TKIs), which have increased penetration into the CNS. [15] [16] [17] Indeed, an ongoing phase 2 cooperative group trial (Radiation Therapy Oncology Group [RTOG] 1119) seeks to further define the role of lapatinib after WBRT or SRS. 18 Given the lack of data reporting the efficacy and toxicity of targeted therapies delivered concurrently with SRS, we sought to define the response to RT among patients with molecular subtypes of breast cancer brain metastases treated with and without these agents. We hypothesized that molecular subtype is prognostic for survival and predictive of the response to RT, and that HER2/EGFR-directed TKIs increase survival, local control, and distant intracranial control.
MATERIALS AND METHODS
This retrospective observational investigation received Institutional Review Board approval and was deemed minimal risk.
Patient Selection and Data Collection
All patients diagnosed with brain metastasis from breast cancer between 1998 and 2014 at a single tertiary care institution were included in an Institutional Review Boardapproved registry. Patients with unknown hormone receptor or HER2 amplification status were excluded. Cohorts were defined according to approximate molecular subtype: hormone receptor-positive, non-HER2-amplified cancers were considered luminal A; hormone receptor-positive, HER2-amplified cancers were considered luminal B; hormone receptor-negative, HER2-positive cancers were considered HER2-enriched (HER21); and hormone receptor-negative, non-HER2-amplified cancers were considered basal-like.
Treatment Delivery
At the discretion of the treating physician, patients underwent WBRT, SRS, and/or surgery. SRS was delivered with a 201-source or 192-source Gamma Knife system (models B, C, 4C, and Perfexion; Elekta Instruments AB, Stockholm, Sweden). After head-frame placement, highresolution (1-mm slice) contrast-enhanced magnetic resonance imaging (MRI) and computed tomography images were acquired. For radiosurgical planning, the dose prescribed to the peripheral margin was chosen based on the lesion diameter according to the RTOG 90-05 protocol. 19 Patients were seen in the clinic with repeat MRI 4 to 6 weeks after WBRT or SRS, and subsequently were followed every 2-3 months.
Outcome Variables
The primary outcome was overall survival, whereas the secondary outcomes included the cumulative incidences of distant intracranial failure, local intracranial failure, and radiation necrosis. Overall survival was calculated from the time of first brain metastasis, whereas secondary outcomes were calculated from the time of completion of RT. Pathologic and/or radiographic data were reviewed to determine intracranial patterns of failure. The presence of new intracranial lesions on follow-up imaging after upfront therapy was defined as distant failure. Enlarged, previously treated ring-enhancing lesions with surrounding edema were suspicious for radiation necrosis versus local progression. 20, 21 Short-interval follow-up imaging was performed to distinguish progressive disease from radiation necrosis using an institutional algorithm. 20 For equivocal cases, a multidisciplinary brain tumor board met to achieve a clinical consensus. If a consensus was not reached, patients typically underwent positron emission tomography, MRI with cerebral blood volume, additional short-interval follow-up imaging, or biopsy/surgical resection to establish a diagnosis of disease recurrence or radiation necrosis.
Statistical Analysis
Data were analyzed on a per-patient (overall survival, distant failure) and per-lesion (local failure, radiation necrosis) basis. Baseline continuous data were compared with Wilcoxon rank sum tests, whereas categorical data were compared with Fisher exact tests. The Kaplan-Meier method was used to determine estimates of overall survival, which were compared with log-rank tests. Cumulative incidence analysis was used to report time-dependent estimates of distant intracranial failure, local failure, and radiation necrosis as described by Gray. 22 Noninformative censoring was performed at the time of loss to radiographic follow-up, with death as a second competing cause. All cumulative incidences were calculated from the date of completion of RT. To compare cumulative incidences, Gray tests were used. 22, 23 Concurrent systemic therapy was defined as an agent administered on the same day as SRS, or within 5 biological half-lives of the date of SRS Original Article (corresponding to approximately 97% metabolism or elimination). Each agent's biological half-life was recorded from the adult Lexi-Drug database. 24 Systemic therapies that were withdrawn >5 biological half-lives before SRS or initiated >5 biological half-lives after SRS were not considered concurrent therapies.
Multivariate Cox proportional hazards regression was used to model overall survival, whereas multivariate competing risks regression was used to model local failure, distant intracranial failure, and radiation necrosis, with death as a competing risk. 25 Models were adjusted for the following covariates: age; sex; the presence of extracranial metastases; number of brain metastases at the time of diagnosis; disease histology; mutational status; treatment with systemic therapies; prior WBRT; prior surgery; conformality index; heterogeneity index; gradient index; and lesion laterality, location, and maximum diameter. Covariates demonstrating an association (P.10) with primary and secondary outcomes on univariate analysis were evaluated in a multivariate model including all 2-way interactions. Covariate inclusion into the final model required a P value .10. Analyses were conducted using the R cmprsk statistical software package. 26, 27 Two-sided tests with a P value < .05 were considered to be statistically significant.
RESULTS

Patient and Treatment Characteristics
Within the study period, a total of 547 patients presented with 3224 brain metastases and met the inclusion criteria ( Table 1 ). The most common molecular subtype was basal-like (31%), followed by luminal A (27%), luminal B (24%), and HER21 (18%). The median time from the 129 (24) 34 (23) 33 (25) 28 (28) 34 (20 (17) 18 (12) 23 (17) 22 (22) 28 (17) .241
Abbreviations: 1 , positive; DS-GPA, disease-specific graded prognostic assessment; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; SRS, stereotactic radiosurgery; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy. a Values are presented as the number (percent) or median (range). b Any use after brain metastasis (subtotals may exceed 100%). c Folate analog, topoisomerase inhibitor, eribulin, platinum agents, or epothilones.
development of metastatic disease to first brain metastasis was 11.1 months, and was longest for the luminal A subtype (17.4 months), followed by luminal B (12.9 months), HER21 (11.4 months), and basal-like (2.1 months) (P 5 .001). At the time of presentation with brain metastasis, the basal-like cohort was found to be least likely to have extracranial metastasis (76%; P 5 .037), although the range among the cohorts was narrow (76%-88%). Among all patients, 36% underwent upfront SRS, 78% underwent upfront WBRT, and 15% underwent upfront surgical resection. Among patients with hormone receptor-positive disease, 83% received hormone therapy after brain metastasis. Among patients with HER2-amplified disease, 80% received HER2 antibodies and 38% received HER2/ EGFR TKIs (ie, lapatinib). Nearly all HER2 antibodies were trastuzumab alone, rather than pertuzumab (2%) or trastuzumab emtansine (T-DM1) (4%). Among all patients, 63% received a course of cytotoxic chemotherapy after brain metastasis.
Overall Survival
The unadjusted median survival after brain metastasis was found to be significantly shorter in the basal cohort (8. (Fig. 1A) . The median radiographic follow-up was 10.1 months, with the vast majority of patients followed until death (80%). Only 12% of patients were lost to follow-up within the 12 months after developing brain metastasis. Among patients with hormone receptorpositive disease, the use of hormone therapies after brain metastasis was not found to be associated with a longer median survival (15.3 months vs 13.9 months; P 5 .21). In contrast, the median survival was longer with the use of both HER2 antibodies (17.9 months vs 15.1 months; P 5 .04) (Fig. 1B) .63
Abbreviations: 1 , positive; 95% CI, 95% confidence interval; EGFR, epidermal growth factor receptor; Gy, grays; HER2, human epidermal growth factor receptor; HR, hazard ratio; TKI, tyrosine kinase inhibitor;
WBRT, whole-brain radiotherapy.
a Any use after brain metastasis (survival) or delivered concurrently with stereotactic radiosurgery (local failure, radiation necrosis).
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Location .123
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.014
Other c 2 (1)
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Prior/concurrent WBRT 575 (67) 106 (54) 263 (82) 114 (73) 92 (49) <.001
Prior/concurrent surgery 167 (19) 34 (17) 66 (21) 23 (15) 44 (24) .154
Maximum diameter (interquartile range), cm .009
Prescription dose (interquartile range), Gy 24 (18) (19) (20) (21) (22) (23) (24) 24 (21) (22) (23) (24) 24 (18-24) 24 (18-24) 24 (18) (19) (20) (21) (22) (23) (24) .087
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Local Failure After SRS
After the diagnosis of brain metastasis, 222 patients underwent SRS to 864 lesions ( Table 4 ). The majority of these metastases (67%) also received WBRT. The most commonly treated molecular subtype was luminal B (322 lesions; 37%). SRS was delivered within 5 half-lives of cytotoxic chemotherapy for 337 metastases (39%). Among patients with hormone receptor-positive metastases, 79% underwent SRS with concurrent hormone therapies. Among patients with HER2-amplified metastases, 78% received HER2 antibodies and 33% received HER2/ EGFR TKIs concurrently with SRS (Table 4) . After SRS, the median radiographic follow-up was 11.6 months, and the greatest radiographic follow-up was observed in the HER21 cohort (19.4 months; P<.001).
The 12-month cumulative incidences of local failure among molecular subtypes were 6.0% in luminal A (95% CI, 2.5%-9.4%), 10.3% in luminal B (95% CI, 7.0%-13.6%), 15.4% in HER21 (95% CI, 9.7%-21.1%), and 9.9% in basal (95% CI, 5.5%-14.2%) (P 5 .01) ( Fig. 2A) . Concurrent chemotherapy decreased the 12-month cumulative incidence of local failure from 12.1% (95% CI, 9.3%-15.0%) to 7.4% (95% CI, 4.6%-10.2%) (P 5 .010) (Fig. 2B) . The 12-month cumulative incidences of local failure after SRS with or without WBRT were 6.9% and 11.0%, respectively (P 5 .02).
Among HER2-amplified lesions (479 lesions), concurrent HER2/EGFR TKIs with SRS significantly decreased the 12-month cumulative incidence of local failure from 15.1% (95% CI, 11.1%-19.0%) to 5.7% (95% CI, 2.1%-9.4%) (P<.001) (Fig. 2C) . Similarly, concurrent HER2 antibodies decreased the 12-month cumulative incidence from 18.4% (95% CI, 10.9%-26.0%) to 10.2% (95% CI, 7.1%-13.3%) (P 5 .003) (Fig. 2D ). Among patients with hormone receptor-positive lesions (520 patients), concurrent hormone therapy with SRS did not significantly decrease the 12-month cumulative incidence of local failure (9.6% vs 5.6%; P 5 .31). After multivariate competing risks regression, the luminal B (HR, 2.28; 95% CI, 1.34-3.91 [P 5 .003]) and HER21 (HR, 3.49; 95% CI, 1.92-6.33 [P<.001]) subtypes were found to be associated with an increased rate of local failure compared with the basal subtype, whereas HER2/EGFR TKIs (HR, 0.42; 95% CI, 0.20-0.88 [P 5 .02]) and HER2 antibodies (HR, 0.62; 95% CI, 0.38-1.00 [P 5 .048]) were associated with a decreased rate of failure (Table 2) . Concurrent chemotherapy no longer remained significantly associated with local failure on multivariate analysis (HR, 0.98; 95% CI, 0.59-1.61 [P 5 .93]).
Radiation Necrosis After SRS
The incidence of radiation necrosis after SRS was 5.6% (48 lesions). The 12-month cumulative incidences of necrosis among molecular subtypes were 1.6% in luminal A (95% CI, 0.0%-3.5%), 5.0% in luminal B (95% CI, 2.6%-7.4%), 3.8% in HER21 (95% CI, 0.8%-6.9%), and 3.9% in basal (95% CI, 1.0%-6.7%) (P 5 .04). Among HER2-amplified lesions (479 lesions), concurrent HER2/EGFR TKIs with SRS was associated with a lower 12-month cumulative incidence of radiation necrosis (1.3% vs 6.3%; P 5 .001). The use of concurrent HER2 antibodies did not appear to significantly impact the rate of radiation necrosis at 12 months (4.3% vs 5.8%; P 5 .30). After multivariate competing risks regression, luminal B metastases were found to be independently associated with an increased rate of radiation necrosis compared with the basal subtype (HR, 2.21; 95% CI, 1.04-4.66 [P 5 .04]), whereas the use of HER2/EGFR TKIs was associated with a lower rate of radiation necrosis (HR, 0.23; 95% CI, 0.07-0.78 [P 5 .02]).
DISCUSSION
In this large institutional study of nearly 550 patients treated for > 3200 brain metastases, we hypothesized and observed that molecular subtypes of breast cancer are prognostic for survival and predictive of the response to RT. Within the HER2-amplified population, concurrent HER2/EGFR TKIs improved local control after SRS, with evidence suggesting that these targeted agents also may decrease the rate of distant intracranial failure. These data are hypothesis-generating, and may support the use of concurrent SRS with TKIs among patients without extracranial disease.
In the HER2-amplified population, we observed a significantly extended survival with the use of HER2 antibodies (17.9 months vs 15.1 months; P 5 .04) (Fig. 1B) and HER2/EGFR TKIs (21.1 months vs 15.4 months; P 5 .03) (Fig. 1C) . Some data have suggested that local control is worse after treatment of HER2-amplified metastases compared with non-HER2-amplified metastases, albeit in small populations without consideration of competing risks. 15, 16 When comparing across molecular subtypes, it is important to recognize that extended survival may itself be responsible for higher rates of failure given the competing risk of death.
Among select patients with targetable metastatic disease, prior investigations have reported superior local control with the addition of concurrent TKIs to SRS. 28 We also observed that the addition of concurrent HER2/ EGFR TKIs to SRS significantly decreased the 12-month cumulative incidence of local failure from 15.1% to 5.7% (P < .001) (Fig. 2C) , whereas the use of HER2 antibodies decreased the 12-month cumulative incidence from 18.4% to 10.2% (P 5 .003) (Fig. 2D) . Moreover, the 12-month cumulative incidence of distant failure with concurrent HER2/EGFR TKIs was 9.2%, compared with 18.3% without the use of this agent (P 5 .08). These data would support a paradigm of upfront SRS and HER2-directed therapy, reserving WBRT as a salvage option. This has the potential to reduce neurocognitive toxicity, because 83% of HER2-amplified patients underwent upfront WBRT and survived for a median of 17.4 months.
In 2013, Lin et al reported results from a phase 1 dose-escalation trial of lapatinib plus WBRT. 29 The CNS objective response rate was 79%. Although the study did not meet its prespecified feasibility for toxicity, only 2 grade 3 toxicities (6%) were neurological, and it would appear that the combination of lapatinib plus WBRT does not synergistically increase CNS toxicity. Support of the intracranial efficacy of these agents can be deduced from the phase 2 LANDSCAPE trial, which demonstrated a 66% partial response rate among WBRT-naive patients treated with lapatinib and capecitabine. 17 To further define the role of these targeted therapies, an ongoing cooperative trial (RTOG 1119) currently is randomizing patients to concurrent and maintenance lapatinib or placebo after either SRS or WBRT. 18 Although this combination may offer more durable intracranial control, it will not provide insight into whether SRS or WBRT can be replaced with lapatinib, nor whether a synergistic effect exists.
In the EMILIA trial, superior progression-free survival and reduced toxicity was observed with T-DM1 compared with the combination of lapatinib and capecitabine, casting doubt on the role of lapatinib in HER2-amplified metastatic disease. 30 This is particularly pertinent because increased toxicity from systemic therapies has been associated with poorer overall survival in a randomized trial of SRS and WBRT with or without erlotinib or temozolomide. 31 Furthermore, a secondary analysis of the EMILIA trial demonstrated an overall survival benefit in favor of T-DM1 among patients with stable/treated brain metastases at baseline, without a corresponding progression-free survival benefit. 32 This exploratory analysis suggests that control of extracranial disease with T-DM1 drives the survival benefit, although patients with progressive brain metastases were excluded from enrollment. Indeed, in the CEREBEL trial, the use of lapatinib with capecitabine did not appear to improve the primary prevention of brain metastases compared with trastuzumab with capecitabine. 33 For patients without extracranial disease, concurrent lapatinib with SRS could be beneficial, reserving pertuzumab (first-line) and T-DM1 (second-line) for those with extracranial progression. Recent case series reporting the intracranial efficacy of T-DM1 further complicate decision making, highlighting the need for future investigations and comparisons across antibodies and small-molecule TKIs. 34 Several limitations must be considered when interpreting the results of the current study. As a retrospective investigation, these results are subject to selection biases. The choice of systemic therapy in a nonrandomized population is influenced by prior therapy, performance status, toxicity profile, extracranial disease, and other factors. As a single institutional investigation, these results may be less generalizable to other institutions. Moreover, few patients were treated with T-DM1 or pertuzumab, which now represent the first-line and second-line standards of care, respectively, in patients with HER2-amplified disease. Particular strengths of this investigation include an analysis of local failure, distant failure, and radiation necrosis with and without targeted and cytotoxic therapies in a large population, which distinguishes it from prior investigations reporting survival alone.
Conclusions
Molecular subtypes of breast cancer were found to be prognostic for survival and predictive of the response to RT. Patients with basal-like pathologies remain at an increased risk of both intracranial failure and death, whereas patients with HER2-amplified pathologies are at an increased risk of intracranial failure in the setting of extended survival. Among patients with HER2-amplified disease, the use of HER2 antibodies and HER2/EGFR TKIs were found to significantly extend survival and local control without an increased rate of radiation necrosis. Moreover, HER2/EGFR TKIs may decrease the rate of distant intracranial failure after upfront therapy. To preserve neurocognition, these results support a paradigm of upfront SRS and HER2-directed therapy in the HER2-amplified population, reserving WBRT as a salvage option. Prospective studies are needed to confirm the findings of the current study, particularly among patients with isolated CNS disease.
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